Dataset Information

Utility of Routine Preoperative ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy.

ABSTRACT:

Purpose

We determined the diagnostic performance of ¹⁸F-FDG (fluorodeoxyglucose) positron emission tomography/computerized tomography for detecting nodal metastases in patients with muscle invasive urothelial bladder cancer before radical cystectomy.

Materials and methods

Preoperative ¹⁸F-FDG positron emission tomography/computerized tomography scans (208) were retrospectively reviewed. Scans were routinely performed in 185 patients with muscle invasive urothelial bladder cancer between August 2012 and February 2017, all of whom underwent radical cystectomy and pelvic lymph node dissection. Analyses were stratified by clinical node involvement and chemotherapy status. The diagnostic performance of ¹⁸F-FDG positron emission tomography/computerized tomography was assessed according to sensitivity, specificity, positive predictive value and negative predictive value.

Results

Lymph node metastases at time of pelvic lymph node dissection were present in 21.8% of those without suspicious nodes on computerized tomography (clinically node negative) and 52.6% of those with suspicious nodes on computerized tomography (clinically node positive). Median metastatic focus size was 5 mm. In clinically node negative cases ¹⁸F-FDG positron emission tomography/computerized tomography rarely detected nodal metastases (sensitivity 7% to 23%). In clinically node positive cases negative ¹⁸F-FDG positron emission tomography/computerized tomography was useful in ruling out lymph node metastases (sensitivity 92% to 100%). This study was limited by its mixed population and focus on pelvic nodal metastases only.

Conclusions

¹⁸F-FDG positron emission tomography/computerized tomography appears to be most useful for better characterization of enlarged nodes identified by computerized tomography. Routine preoperative ¹⁸F-FDG positron emission tomography/computerized tomography has limited utility in clinically node negative cases.

SUBMITTER: Dason S

PROVIDER: S-EPMC8477436 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Utility of Routine Preoperative <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy.

Dason Shawn S Wong Nathan C NC Donahue Timothy F TF Meier Andreas A Zheng Junting J Mannelli Lorenzo L Di Paolo Pier Luigi PL Dean Lucas W LW McPherson Victor A VA Rosenberg Jonathan E JE Bajorin Dean F DF Capeanu Marinella M Dalbagni Guido G Vargas H Alberto HA Bochner Bernard H BH

The Journal of urology 20200305 2

<h4>Purpose</h4>We determined the diagnostic performance of <sup>18</sup>F-FDG (fluorodeoxyglucose) positron emission tomography/computerized tomography for detecting nodal metastases in patients with muscle invasive urothelial bladder cancer before radical cystectomy.<h4>Materials and methods</h4>Preoperative <sup>18</sup>F-FDG positron emission tomography/computerized tomography scans (208) were retrospectively reviewed. Scans were routinely performed in 185 patients with muscle invasive uroth ...[more]

PMID: 32134343

Similar Datasets

Project description:PurposeAccurate preoperative staging of prostate cancer is essential for treatment planning. Conventional imaging is limited in detection of metastases. Our primary aim was to determine if [18F]fluciclovine positron emission tomography/computerized tomography is an early indicator of subclinical metastasis among patients with high risk prostate cancer.Materials and methodsA total of 68 patients with unfavorable intermediate to very high risk prostate cancer without systemic disease on conventional imaging were recruited before robotic radical prostatectomy with extended pelvic lymph node dissection. Diagnostic performance of [18F]fluciclovine positron emission tomography/computerized tomography and conventional imaging for detection of metastatic disease, and correlation of positivity to node and metastatic deposit size were determined.ResultsOverall 57 of 68 patients completed the protocol, of whom 31 had nodal metastasis on histology. [18F]Fluciclovine positron emission tomography/computerized tomography sensitivity and specificity in detecting nodal metastasis was 55.3% and 84.8% per patient, and 54.8% and 96.4% per region (right and left pelvis, presacral and nonregional), respectively. Compared with conventional imaging [18F]Fluciclovine positron emission tomography/computerized tomography had significantly higher sensitivity on patient based (55.3% vs 33.3%, p <0.01) and region based (54.8% vs 19.4%, p <0.01) analysis, detecting metastasis in 7 more patients and 22 more regions, with similar high specificity. Four additional patients had distant disease or other cancer detected on [18F] fluciclovine positron emission tomography/computerized tomography which precluded surgery. Detection of metastasis was related to size of metastatic deposits within lymph nodes and overall metastatic burden.Conclusions[18F]Fluciclovine positron emission tomography/computerized tomography detects occult metastases not identified on conventional imaging and may help guide treatment decisions and lymph node dissection due to high specificity for metastatic disease.

Project description:Subthalamic nucleus (STN) deep brain stimulation (DBS) can improve motor symptoms in Parkinson's disease (PD), as well as potentially improving otherwise intractable comorbid depressive symptoms. To address the latter issue, we evaluated the severity of depressive symptoms along with the severity of motor symptoms in 18 PD patients (mean age, 58.4 ± 5.4 years; 9 males, 9 females; mean PD duration, 9.4 ± 4.4 years) with treatment-resistant depression (TRD) before and after approximately 1 year of STN-DBS treatment. Moreover, to gain more insight into the brain mechanism mediating the therapeutic action of STN-DBS, we utilized 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to assess cerebral regional glucose metabolism in the patients at baseline and 1-year follow-up. Additionally, the baseline PET data from patients were compared with PET data from an age- and sex-matched control group of 16 healthy volunteers. Among them, 12 PD patients underwent post-operative follow-up PET scans. Results showed that the severity of both motor and depressive symptoms in patients with PD-TRD was reduced significantly at 1-year follow-up. Also, patients used significantly less antiparkinsonian medications and antidepressants at 1-year follow-up, as well as experiencing improved daily functioning and a better quality of life. Moreover, relative to the PET data from healthy controls, PD-TRD patients displayed widespread abnormalities in cerebral regional glucose metabolism before STN-DBS treatment, which were partially recovered at 1-year follow-up. Additionally, significant correlations were observed between the patients' improvements in depressive symptoms following STN-DBS and post-operative changes in glucose metabolism in brain regions implicated in emotion regulation. These results support the view that STN-DBS provides a promising treatment option for managing both motor and depressive symptoms in patients who suffer from PD with TRD. However, the results should be interpreted with caution due to the observational nature of the study, small sample size, and relatively short follow-up.

Project description:BackgroundAccurately predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer remains a clinical challenge. Current imaging-based models are limited in their ability to integrate key metabolic parameters to enhance prediction accuracy. This study aimed to develop and validate a nomogram using 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) parameters, including maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), to improve pCR prediction. These parameters, representing both tumor metabolic burden and activity, were hypothesized to collectively provide a robust means of predicting pCR.MethodsThis retrospective cohort study enrolled 95 breast cancer (BC) patients who underwent 18F-FDG PET/CT before and after NACT. Patients were categorized into pCR (n=46) and non-pCR (n=49) groups based on postoperative pathological outcomes. Clinical and pathological characteristics, as well as changes in SUVmax, MTV, and TLG, were compared between the two cohorts. Logistic regression identified independent predictors of non-pCR. The dataset was then randomly divided into training (n=66) and validation (n=29) cohorts for nomogram construction and validation. The model's performance was evaluated using the area under the receiver operating characteristic (ROC) curve, calibration curves, and decision curve analysis.ResultsRelative to the non-pCR cohort, the pCR group exhibited smaller tumor diameters, lower Ki-67 expression, fewer lymph node metastases, and higher proportions of HER2+ molecular subtype (P<0.05). Pretreatment SUVmax, MTV, and TLG levels in the pCR group were significantly lower than those in the non-pCR group, and showed a marked decrease after treatment (P<0.05), whereas no significant changes were observed in the non-pCR group (P>0.05). SUVmax, MTV, TLG, and molecular subtype were identified as independent predictors of non-pCR through logistic regression analysis. A nomogram constructed using these predictors achieved area under the ROC curve (AUC) of 0.9003 and 0.9363 in the training and validation cohorts, respectively. The model demonstrated good calibration (Hosmer-Lemeshow test, χ2=6.412, P=0.60) and clinical utility through decision curve analysis, effectively stratifying patients at high risk of non-pCR based on a cutoff value of 0.8230.Conclusions18F-FDG PET/CT demonstrates significant clinical value in predicting pCR to NACT in BC patients. By integrating metabolic parameters such as SUVmax, MTV, and TLG into a nomogram, this approach enables accurate prediction of treatment efficacy, aiding in the early identification of patients unlikely to benefit from NACT. This facilitates timely adjustments to personalized treatment plans, optimizing clinical outcomes and resource allocation.

Project description:PurposeThis study aims to assess the predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) radiological features and the maximum standardized uptake value (SUVmax) in determining the presence of spread through air spaces (STAS) in clinical-stage IA non-small cell lung cancer (NSCLC).MethodsA retrospective analysis was conducted on 180 cases of NSCLC with postoperative pathological assessment of STAS status, spanning from September 2019 to September 2023. Of these, 116 cases from hospital one comprised the training set, while 64 cases from hospital two formed the testing set. The clinical information, tumor SUVmax, and 13 related CT features were analyzed. Subgroup analysis was carried out based on tumor density type. In the training set, univariable and multivariable logistic regression analyses were employed to identify the most significant variables. A multivariable logistic regression model was constructed and the corresponding nomogram was developed to predict STAS in NSCLC, and its diagnostic efficacy was evaluated in the testing set.ResultsSUVmax, consolidation-to-tumor ratio (CTR), and lobulation sign emerged as the best combination of variables for predicting STAS in NSCLC. Among these, SUVmax and CTR were identified as independent predictors for STAS prediction. The constructed prediction model demonstrated area under the curve (AUC) values of 0.796 and 0.821 in the training and testing sets, respectively. Subgroup analysis revealed a 2.69 times higher STAS-positive rate in solid nodules compared to part-solid nodules. SUVmax was an independent predictor for predicting STAS in solid nodular NSCLC, while CTR and an emphysema background were independent predictors for STAS in part-solid nodular NSCLC.ConclusionOur nomogram based on preoperative 18F-FDG PET/CT radiological features and SUVmax effectively predicts STAS status in clinical-stage IA NSCLC. Furthermore, our study highlights that metabolic parameters and CT variables associated with STAS differ between solid and part-solid nodular NSCLC.

Dataset Information

Utility of Routine Preoperative ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy.

Purpose

Materials and methods

Results

Conclusions

Publications

Utility of Routine Preoperative <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Utility of Routine Preoperative 18F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy.

Purpose

Materials and methods

Results

Conclusions

Publications

Utility of Routine Preoperative <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Utility of Routine Preoperative ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy.